Pharmafile Logo
Pharmafocus logo
Advanced Search

GBI Research

Showing 4 posts of 4 posts found.

shutterstock_141105490

Asia-Pacific flu market to hit $1.71bn by 2022

January 20, 2017
Business Services, Medical Communications APAC, GBI Research

According to new data from intelligence provider GBI Research, the flu vaccines market in the Asia-Pacific (APAC) region is set …

News
shutterstock_311949818

Neurodegenerative market to be worth $45 billion by 2022

December 12, 2016
Sales and Marketing Biogen, GBI Research, Novartis, Roche, Sanofi, neurodegenerative

Neurodegenerative disorders including Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) form a lucrative worldwide market which …

News
Pills image

OTC drugs market boosted by growing patient demand

December 24, 2015
Manufacturing and Production, Sales and Marketing GBI Research, OTC, generics, over the counter

Increasing pressures from customers, drug manufacturers and regulators to convert prescription medications to over-the-counter (OTC) non-prescription status is driving growth …

News
lung cancer x ray

Lung cancer market to hit $10.9bn by 2021

September 10, 2015
Sales and Marketing AZD9291, GBI Research, GlobalData, NSCLC, industry analysis, industry intelligence, industry reports, keytruda, market intelligence lung cancer, market reports, market trends, non small cell lung cancer, non-small cell lung cancer, opdivo, world conference on lung cancer

The global market value for non-small cell lung cancer treatment will rise from $6.9 billion in 2014 to $10.9 billion …

News

Latest content

Sanofi shares results from phase 2 trial for frexalimab in MS treatment

July 1, 2024

EMA accepts AstraZeneca’s regulatory submission for sipavibart for COVID-19 prevention

July 1, 2024

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024